Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center

Neurol Sci. 2020 Dec;41(Suppl 2):483-484. doi: 10.1007/s10072-020-04667-0.

Authors

Affiliations

¹ Department of Biomedical and NeuroMotor Sciences (DiBiNeM), Bellaria Hospital, Alma Mater Studiorum - University of Bologna, Via Altura 3, 40139, Bologna, Italy.
² IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
³ IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. s.cevoli@isnb.it.

PMID: 32860531
DOI: 10.1007/s10072-020-04667-0

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Calcitonin Gene-Related Peptide Receptor Antagonists
Headache
Humans
Migraine Disorders* / drug therapy
Migraine Disorders* / epidemiology

Substances

Antibodies, Monoclonal, Humanized
Calcitonin Gene-Related Peptide Receptor Antagonists
erenumab